Genitourinary Cancer

Genitourinary Cancer

29 items identified
A031801: Advanced Renal Cell Carcinoma with Bone Metastasis
Alliance-A031704/PDIGREE (Renal Cell Cancer)
AMG 509 in patients with mCRPC (Prostate Cancer)
AVB-S6-500 in patients with advanced or metastatic clear cell renal cell carcinoma
Bellicum BPX-601 (Prostate Cancer)
C3891001 - Integrin blockade in metastatic GU cancers (Renal Cell Carcinoma)
CG0070 in NMIBC Unresponsive to BCG - BOND-003 (Bladder Cancer)
CHAMP (Prostate Cancer)
COMPPARE for prostate cancer
Coping Together-2 (Cancer Support)
CTC - Immune Based Biomarkers (Kidney & Bladder Cancer)
EV-103 enfortumab vedotin alone or with other therapies for urothelial cancer
Expand URO (Genitourinary Cancers that Require Surgery)
FEATURES OF PRIMARY AND ADAPTIVE IMMUNOTHERAPY RESISTANCE IN MICROSATELLITE INSTABLE CANCERS
Infigratnib in Invasive UC - PROOF 302 (Urothelial Carcinoma)
Intravesical Enfortumab Vedotin in Non-Muscle Invasive Bladder Cancer
Keynote B15 - EV/Pembro vs GEM/CIS in muscle-invasive bladder cancer
Merck LiteSpark-011: Advanced rCC progression after immunotherapy (Renal Cell Carcinoma)
Merck Prostate 365 - Combination therapies for mCRPC (Prostate Cancer)
Merck U03B: Targeted combination therapies for second line ccRCC patients (Renal Cell Cancer)
NRG-GU009 (Prostate Cancer)
OncoCHAT (Advanced Solid Cancer)
Propella: Intramuscular abiraterone decanoate for metastatic prostate cancer
PSMAfore: Lu-PSMA for men with castrate-resistant prostate cancer
SPARC: Prostatectomy +/- Cabozantinib in High-Risk Prostate Cancer Patients
Stellar-002: XL-092 (Kidney, Bladder, and Prostate Cancer)
Synthekine STK-012 (Solid Tumors)
TAR-200/Cetrelimab vs. chemoradiotherapy in MIBC (Bladder Cancer)
Tyra SURF-301: Phase 1/2 study for patients with urothelial carcinoma and an FGFR3 alteration